^
PD-L1 expression
Cervical Cancer
pembrolizumab + bevacizumab
Sensitive: A1 - Approval
FDA - 4 days
KDR expression
Cervical Cancer
recombinant human endostatin
Sensitive: C3 – Early Trials
Oncol Res - 3 weeks
No biomarker
Cervical Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Cervical Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Cervical Cancer
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Cervical Cancer
bevacizumab
Sensitive: A1 - Approval
No biomarker
Cervical Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Cervical Cancer
tisotumab vedotin-tftv
Sensitive: A1 - Approval
No biomarker
Cervical Cancer
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Cervical Cancer
paclitaxel + topotecan
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
carboplatin
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
pemetrexed
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
mitomycin
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
irinotecan
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
ifosfamide
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
topotecan
Sensitive: A2 - Guideline
NTRK3 fusion
Cervical Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Cervical Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Cervical Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Cervical Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Cervical Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Cervical Cancer
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
cisplatin
Sensitive: A2 - Guideline
TMB-H
Cervical Cancer
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Cervical Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
cisplatin + topotecan
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
CaT
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
CPB
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
VC
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
EP
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
CP
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
TPB
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
carboplatin + etoposide oral
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
cisplatin + etoposide oral
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Cervical Cancer
AGEN2034 + AGEN1884
Sensitive: B - Late Trials
No biomarker
Cervical Cancer
AGEN2034
Sensitive: B - Late Trials
No biomarker
Cervical Cancer
pembrolizumab + bevacizumab
Sensitive: B - Late Trials
No biomarker
Cervical Cancer
pembrolizumab
Sensitive: B - Late Trials
MSI-H/dMMR
Cervical Cancer
nivolumab + ipilimumab
Sensitive: C1 - Off-label
HER-2 overexpression
Cervical Cancer
trastuzumab
Resistant: C1 - Off-label
HER-2 mutation
Cervical Cancer
neratinib
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Cervical Cancer
AB122
Sensitive: C2 – Inclusion Criteria
DDR
Cervical Cancer
BAY1895344
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Cervical Cancer
HLX10
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Cervical Cancer
AGEN2034
Sensitive: C2 – Inclusion Criteria
PRDX2 overexpression
Cervical Cancer
cisplatin
Resistant: C3 – Early Trials
PRDX1 overexpression
Cervical Cancer
cisplatin
Resistant: C3 – Early Trials
AJUBA overexpression
Cervical Cancer
cisplatin
Resistant: C3 – Early Trials
IFNG gene signature overexpression
Cervical Cancer
nivolumab + BMS-986205
Sensitive: C3 – Early Trials
PD-L1 expression
Cervical Cancer
anlotinib + sintilimab
Sensitive: C3 – Early Trials
FGFR3-TACC3 F17T8
Cervical Cancer
ABSK-091
Sensitive: C3 – Early Trials
CXCL8 elevation
Cervical Cancer
ipilimumab
Resistant: C3 – Early Trials
TNFA elevation
Cervical Cancer
ipilimumab
Resistant: C3 – Early Trials
IL6 elevation
Cervical Cancer
ipilimumab
Resistant: C3 – Early Trials
PD-L1 expression
Cervical Cancer
rivoceranib + camrelizumab
Sensitive: C3 – Early Trials
TXN overexpression
Cervical Cancer
cisplatin
Resistant: C3 – Early Trials
PD-L1 negative
Cervical Cancer
AGEN2034
Sensitive: C3 – Early Trials
STK11 mutation
Cervical Cancer
anlotinib + sintilimab
Resistant: C3 – Early Trials
KMT2D mutation
Cervical Cancer
anlotinib + sintilimab
Sensitive: C3 – Early Trials
PIK3CA mutation
Cervical Cancer
anlotinib + sintilimab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Cervical Cancer
pembrolizumab
Sensitive: C3 – Early Trials
BRCA2 exon 11 deletion
Cervical Cancer
ABSK-091
Sensitive: C4 – Case Studies
BRCA1 mutation + TP53 R248Q
Cervical Cancer
olaparib + bevacizumab
Sensitive: C4 – Case Studies
BRCA1 positive
Cervical Cancer
olaparib + bevacizumab
Sensitive: C4 – Case Studies
MAPK4 deletion
Cervical Cancer
PARP inhibitor
Sensitive: D – Preclinical
RAD51 underexpression
Cervical Cancer
olaparib
Sensitive: D – Preclinical
HUWE1 mutation
Cervical Cancer
GS-626510
Sensitive: D – Preclinical
MYC overexpression
Cervical Cancer
GS-626510
Sensitive: D – Preclinical
ROR1 expression
Cervical Cancer
sirolimus
Sensitive: D – Preclinical
TROP2 expression
Cervical Cancer
sacituzumab govitecan-hziy
Sensitive: D – Preclinical
PIK3CA mutation
Cervical Cancer
neratinib + copanlisib
Sensitive: D – Preclinical
HER-2 mutation
Cervical Cancer
afatinib
Sensitive: D – Preclinical
NCL overexpression
Cervical Cancer
QN-165
Sensitive: D – Preclinical
TBX1 overexpression
Cervical Cancer
cisplatin
Sensitive: D – Preclinical
NCL overexpression
Cervical Cancer
cisplatin
Resistant: D – Preclinical
DIRAS3 overexpression
Cervical Cancer
paclitaxel
Sensitive: D – Preclinical